Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 107

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 107
---
 Material Contracts; |

| (C) | any applicable Laws; |

| (D) | any note, bond, mortgage, indenture, instrument, Contract, agreement, lease, Authorization or government grant 
 or license to which the Company or its Subsidiary is party or by which it is bound; or                         |

| (E) | any Order; |

| (ii) | give rise to any right of termination, amendment, acceleration or cancellation of indebtedness of the Company                                                                                                                                         
 or any Subsidiary of the Company, or cause any credit available to the Company or any Subsidiary of the Company which is material to the Company and the Subsidiary of the Company, taken as a whole, to cease to be available, or cause any security 
 interest in any assets of the Company or the Subsidiary of the Company to become enforceable or realizable;                                                                                                                                           |

| (iii) | give rise to any or other change of any right or obligation or the loss of any benefit to which the Company or                                                                                                                                            
 the Subsidiary is entitled (including by triggering any rights of first refusal or first offer, change in control provision or other restriction or limitation) under any such note, bond, mortgage, indenture, Contract, agreement, lease, Authorization 
 or government grant or license; or                                                                                                                                                                                                                        |

| (iv) | result in the imposition of any Encumbrance upon any assets of the Company or the Subsidiary. |

| (b) | No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental                                                                                                                                          
 Entity is required to be obtained by the Company in connection with the consummation of the Contemplated Transactions or the Distribution other than those which are expressly contemplated by the Plan of Arrangement and this Agreement and except as 
 would not, individually or in the aggregate, reasonably be expected to be material to the Company or be reasonably likely to materially delay the consummation of the Contemplated Transactions.                                                        |

E-2

| (c) | To the knowledge of the Company, there are no pending changes to applicable Laws or governmental position that 
 could reasonably be expected to materially affect the Discontinuance.                                          |

| 5. | Subsidiaries |

The Company has no subsidiaries and no direct or indirect interest in any other corporation, association, incorporated joint venture or other entity, other than the Subsidiary. The Company owns, directly or indirectly,